PTGS2 and lung carcinoma: In contrary to the less COX-2-selective celecoxib [63], etoricoxib had no negative impact on alveolar bone healing in rats [64], whereas a reported antiangiogenetic effect in experimental lung cancer [65] was not observed at the etoricoxib concentrations used in our study.